At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1/2 Study of Suberoylanilide Hydroxamic Acid (SAHA, Vorinostat) and Local Irradiation, Followed by Maintenance SAHA in Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas (DIPG)
In Brief
A Phase 2 clinical trial evaluating 3-Dimensional Conformal Radiation Therapy, Intensity-Modulated Radiation Therapy, and 2 other interventions for Anaplastic Astrocytoma and 3 related conditions. Completed, enrolled 79 participants across 180 sites in 3 countries.
Detailed Summary
This phase I/II trial studies the side effects and best dose of vorinostat and to see how well it works when given together with radiation therapy followed by maintenance therapy with vorinostat in treating younger patients with newly diagnosed diffuse intrinsic pontine glioma (a brainstem tumor). Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving vorinostat together with radiation therapy may kill more tumor cells.
Study Details
Timeline
Interventions
Undergo 3D conformal radiation therapy
Undergo intensity-modulated radiation therapy
Correlative studies
Given PO